A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors

A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors

A phase I study evaluated the safety, tolerability, and maximum-tolerated dose (MTD)/recommended phase II dose (RP2D) of FCN-437c, a novel, orally available cyclin-dependent kinase inhibitor (CDK4/6i), in participants with advanced/metastatic solid tumors (aSTs). FCN-437c was escalated from 50 mg (o...

Full description

Bibliographic Details
Main Authors: Amita Patnaik, Erika Hamilton, Yan Xing, Drew W. Rasco, Lon Smith, Ya-Li Lee, Steven Fang, Jiao Wei, Ai-Min Hui
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cancers
Subjects:
FCN-437c
CDK4/6 inhibitor
advanced solid tumors
phase I
Online Access:https://www.mdpi.com/2072-6694/14/20/4996

Internet

https://www.mdpi.com/2072-6694/14/20/4996

Similar Items